The FDA has approved a single-vial formulation of docetaxel injection from Hospira, a generic version of Taxotere (sanofi-aventis). Hospira anticipates that docetaxel injection will be made available in late March 2011 in a 10mg/mL concentration in 20mg, 80mg, and 160mg vials.

Docetaxel is a chemotherapeutic agent indicated for use in treating patients at specific stages of five types of cancer: metastatic and adjuvant breast cancer, metastatic androgen-independent prostate cancer, advanced non-small cell lung cancer, advanced gastric adenocarcinoma and locally advanced squamous cell carcinoma of the head and neck.

For more information call (800) 615-0187 or visit